skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Can you comment on the prospects and yield for this new listing
Read Answer Asked by Kim on February 04, 2019
Q: Hello 5i,
Us health and cad health stocks give me a headache ! My list of dogs is long and they bite. I’ve even held ibb for three years and sold it at a loss in December! (Gain on the currency- only).
1) should I keep ILMN after this most recent report or technically is it too about to bite?
2) not including big pharma, is there a US asset 5i can suggest that is not too expensive yet shows promise?
Thank you!
Read Answer Asked by Kat on February 04, 2019
Q: Hi 5i,
I know that US stocks are not the main focus but I have been watching Resmed for awhile and saw that it tanked 20% the other day on an off earnings report. This looks to have been a fairly strong stock over the last few years. Any comments you can make on them? Would they fit in your US growth stock list?

Thank you
Read Answer Asked by David on February 03, 2019
Q: 5I Team,

I know that US equities isn't your bailiwick, but I would appreciate any comments you may have on Akoustis Technologies Inc. (NASDAQ: AKTS).

Thanks
Read Answer Asked by Scott on January 30, 2019
Q: ISRG was down about 4% Friday on general concerns about spending and increased competition from J&J and Google amongst others. I’m not sure what the fuss is all about since competition is just a fact of life and to the best of my knowledge neither J&J nor Google have any experience building medical devices.
It’s reported ISRG earned $2.96 a share, missing expectations by 2-11 cents per share. However ISRG reported profit was cut by 16 cents per share due to a payment to the Intuitive Foundation. Is the foundation part of the research arm of ISRG and why a foundation? Would ISRG have exceeded expectations if they hadn’t payed money to the foundation and did the analysis’s anticipate the donation to the the foundation?
I am contemplating buying the dip a little bit or do you think I should hold off?
Thanks for you prompt response on Conmed! (I don’t count the weekend as part of the 36 hour commitment).
Jim
Read Answer Asked by James on January 30, 2019
Q: Hello,
Raymond James analyst downgraded SQ to underperform. "In short, we believe organic growth peaked in 3Q18 and growth on the all-important [subscription] and services line will likely materially decelerate in 2Q19. What do you think about this opinion? Do you still think its a buy?
Thanks
Victor
Read Answer Asked by Victor on January 29, 2019